Johnson & Johnson’s Ethicon 4000 Stapler Secures CE Mark Ahead of Ottava Robotic Platform Launch in Europe

Source of the article:MedRobot

Reprint Requirements: You can directly repost, but please credit the source at the beginning of the article.

April 22, 2026Johnson & Johnson announced that Ethicon 4000 stapler has obtained CE Mark certification, covering two types of indications for open surgery and laparoscopic surgery within the European Union.The product was launched in mid-2025, with FDA approval (applicable to both open and laparoscopic surgeries) obtained prior to this EU certification. This CE Mark officially opens the European market commercialization pathway for Ethicon 4000 and forms part of J&J’s surgical robotics platform Ottava’s device pre-positioning strategy — Ottava remains in the research phase globally, with both the CE Mark and FDA de novo approval still pending.

# Ethicon 4000 Product Analysis

Ethicon 4000 is a linear cutting stapler, and J&J labels its core technology as"Proprietary 3D Stapling Technology"The mechanism lies in"Leg Nail Offset Closure"The upper and lower rows of staple legs in traditional 2D staplers compress symmetrically and synchronously during closure, with the forming pressure along the entire staple line decreasing from both ends towards the middle section. This can easily lead to localized insufficient pressure or over-clamping in areas where tissue thickness is uneven. The 3D design theoretically improves sealing uniformity across regions of varying tissue thickness by staggering the closure timing of adjacent staple legs, causing pressure to be alternately distributed along the longitudinal direction of the staple line. J&J cited internal data stating,Compared with traditional 2D staples, Ethicon 4000 can reduce staple line interventions due to bleeding by 23%.

In terms of end effectors,Ethicon 4000 adopts a redesigned version, and J&J's statement focuses on"Consistency from the first staple to the last staple," referring to the stable output of clamping force and cutting force during the firing process.——This is a common issue where traditional staplers experience performance degradation after multiple firings or reload changes. The accompanying consumables are "Ethicon 3D Reloads," specifically designed for this platform and not interchangeable with the standard reload system used in the previous Echelon series, forming an independent closed-loop of consumables.

In terms of the scope of indications, the CE Mark approves its use in open and laparoscopic surgeries across multiple departments, including general surgery, thoracic surgery, urology, and gynecology, rather than being a single-specialty instrument.This aligns with J&J's subsequent strategy to integrate it into the Ottava multi-department surgical scenarios — Ottava's product positioning itself as a cross-department soft tissue surgery platform, rather than like the early da Vinci, which focused on urology as its core breakthrough.

# Ottava Pre-launch: Stapler Enters Market Before Robot

Johnson & Johnson clearly stated,The technical pathway of Ethicon 4000 will support the future applications of Ottava.In terms of timing, the stapler completed regulatory access in the two major markets before the robotic platform, and this sequence was no accident.

Intuitive Surgical has previously followed a similar path:The EndoWrist series of staplers are deeply integrated with the da Vinci system, creating a closed ecosystem of instruments, and surgeons' operational habits with dedicated instruments further enhance platform stickiness.J&J's current operational logic is highly similar — during the period when Ottava is awaiting approval, it aims to build surgeon familiarity and trust in Ethicon 4000 in Europe. Once Ottava is approved, the friction involved in switching to accompanying instruments will be significantly reduced. However, Ottava has not yet announced any timeline for the release of clinical data or confirmed an entry point for any market, leaving the "robot pre-positioning" narrative currently at the level of a strategic signal without a quantifiable market timeline to match.

# Competitive Reference

Comparison of Main Surgical Stapler Platforms and Robot Compatibility (April 2026)

The differences in three dimensions need to be clearly distinguished: Intuitive's EndoWrist Stapler is a robot-specific solution, with the 7 degrees of freedom wrist joint being its core design barrier, but at the cost of being deeply locked into the da Vinci system; Medtronic's Signia series currently has no public disclosure regarding the depth of instrument integration with the Hugo RAS; J&J Ethicon 4000 adopts"Open/Laparoscopic Surgery Approved First, Followed by Robotic Integration"The path,While not relying on the robot platform for initial implementation, it retains the narrative space for migration to Ottava.These two methodologies — "Robot-Specific Design" and "Cross-Platform Compatible Late Binding" — correspond to different market entry rhythms and device lifecycle logics. Before the approval result of Ottava is finalized, it remains inconclusive which approach is superior.

# MedRobot Observation

The CE Mark for Ethicon 4000 is itself a routine regulatory advancement, but in the context of Ottava's approval, it reveals a specific strategic choice by J&J in their device market entry approach:Without waiting for the regulatory conclusion of the robotic platform, establish a clinical presence in the target market first through independent device approval.

The practical logic behind this strategy is that Ottava's de novo pathway means the FDA has no substantially equivalent product to refer to, leading to significant uncertainty in the approval timeline; the CE Mark process also faces challenges in estimating milestones due to Ottava being a new category. In this context, fully decoupling the approval processes of Ethicon 4000 and Ottava allows the stapler to advance independently toward commercialization while building a user base compatible with Ottava in clinical settings, serving as a reasonable hedge against platform approval uncertainties.